Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Karuna Therapeutics, Inc is a biotechnology business based in the US. Karuna Therapeutics shares (KRTX) are listed on the NASDAQ and all prices are listed in US Dollars. Karuna Therapeutics employs 19 staff and has a market cap (total outstanding shares value) of USD$2.8 billion.
|Latest market close||USD$97.85|
|52-week range||USD$52.62 - USD$123.73|
|50-day moving average||USD$99.8076|
|200-day moving average||USD$89.9832|
|Wall St. target price||USD$128.18|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-254.14|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-08)||-8.67%|
|1 month (2020-12-16)||-2.63%|
|3 months (2020-10-16)||26.32%|
|6 months (2020-07-15)||2.45%|
|1 year (2020-01-15)||14.71%|
|2 years (2019-01-12)||N/A|
|3 years (2018-01-12)||N/A|
|5 years (2016-01-12)||N/A|
Valuing Karuna Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Karuna Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Karuna Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, Karuna Therapeutics shares trade at around 0x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
|Gross profit TTM||USD$0|
|Return on assets TTM||-13.31%|
|Return on equity TTM||-20.13%|
|Market capitalisation||USD$2.8 billion|
TTM: trailing 12 months
There are currently 1.5 million Karuna Therapeutics shares held short by investors – that's known as Karuna Therapeutics's "short interest". This figure is 8.2% down from 1.6 million last month.
There are a few different ways that this level of interest in shorting Karuna Therapeutics shares can be evaluated.
Karuna Therapeutics's "short interest ratio" (SIR) is the quantity of Karuna Therapeutics shares currently shorted divided by the average quantity of Karuna Therapeutics shares traded daily (recently around 127959.68992248). Karuna Therapeutics's SIR currently stands at 11.61. In other words for every 100,000 Karuna Therapeutics shares traded daily on the market, roughly 11610 shares are currently held short.
However Karuna Therapeutics's short interest can also be evaluated against the total number of Karuna Therapeutics shares, or, against the total number of tradable Karuna Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Karuna Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Karuna Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.1222% of the tradable shares (for every 100,000 tradable Karuna Therapeutics shares, roughly 122 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Karuna Therapeutics.
Find out more about how you can short Karuna Therapeutics stock.
We're not expecting Karuna Therapeutics to pay a dividend over the next 12 months.
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, primarily focuses on developing novel therapies to address disabling neuropsychiatric disorders and pain. Its lead product candidate is KarXT, an oral modulator that has completed Phase II clinical trial for the treatment of acute psychosis in patients with schizophrenia; and in Phase Ib clinical trial for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, Alzheimer's, and pain, as well as for the treatment of dementia-related psychosis. The company also focuses on developing other muscarinic-targeted drug candidates. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was founded in 2009 and is headquartered in Boston, Massachusetts.
Everything we know about the Vacasa IPO, plus information on how to buy in.
Everything we know about the William Penn Bancorp IPO, plus information on how to buy in.
Everything we know about the Landos Biopharma Inc IPO, plus information on how to buy in.
Everything we know about the First High-School Education Group Co Ltd IPO, plus information on how to buy in.
Everything we know about the Knowlton Development Corp IPO, plus information on how to buy in.
Steps to owning and managing SASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAIL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAF, with 24-hour and historical pricing before you buy.
Steps to owning and managing RDHL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBFG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.